Sharemaestro Newsreel

Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...

This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration …

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

VALNEVA SE Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with …

5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call

5 Must-Read Analyst Questions From Gilead Sciences's Q2 Earnings Call Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management …

Organon & Co To Go Ex-Dividend On August 14th, 2026 With 0.02 USD Dividend Per Share

Organon & Co will go ex-dividend on August 14th, 2026. The company is set to pay a dividend of 0.02 USD per share. This indicates a forthcoming dividend payment for shareholders.

BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...

This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing …

5 Insightful Analyst Questions From Merck’s Q2 Earnings Call

5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic …

Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'

Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly, asserting that competition must be fair and patients deserve full transparency regarding weight-loss drug efficacy. The lawsuit alleges Lilly's advertising for its GLP-1 drugs misleads consumers by comparing them to an older, …

Eli Lilly tries to stop GLP-1 copycats

Eli Lilly has filed six lawsuits against US companies for allegedly selling unauthorized versions of its experimental obesity drug, retatrutide. The drugmaker emphasizes that retatrutide has not received FDA approval and carries significant risks. This action is part of Lilly's broader effort to combat …

Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps

Novo Nordisk's CEO Mike Doustdar admitted that Eli Lilly is gaining market share in the GLP-1 drug market, leading to a slump in Novo's stock despite positive news like raised full-year sales guidance. Doustdar explained that price cuts for Ozempic and Wegovy to increase …

FDA Authorizes Medicus Pharma’s SkinJect Study for Gorlin Syndrome

Medicus Pharma (MDCX) widens loss as it raises $32M and adds secured notes

Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and …

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca Sells 11,699 Shares of Stock

Merck & Co., Inc. EVP Richard Deluca recently sold 11,699 shares of the company's stock for approximately $1.54 million, reducing his stake by 9.6%. This sale follows strong quarterly results where Merck exceeded revenue and adjusted EPS estimates and maintained positive fiscal year 2026 …

Biogen Inc. stock outperforms competitors on strong trading day

Shares of Biogen Inc. (BIIB) rose 2.44% to $208.87 on Wednesday, outperforming the mixed market performance. This gain snapped a two-day losing streak for the company's stock. The S&P 500 Index saw a 0.26% increase, while the Dow Jones Industrial Average dropped 0.04%.

How ABBV Stock Moved Away From Its Peer Group

AbbVie (ABBV) has shown strong fundamental performance with high revenue growth and operating margins, yet its stock returns significantly lag behind peers like Merck and Johnson & Johnson. This disconnect is attributed to the market pricing in future competitive threats to AbbVie's key drug …

Novo Nordisk (NVO) Stock Still Looks Cheap On Earnings But Faces Growth Doubts

Merck & Co. (MRK) EVP Richard DeLuca sells 45,320 shares over three days

Richard R. DeLuca, EVP & President, Merck Animal Health, sold a total of 45,320 shares of Merck & Co. common stock over three days (August 10-12, 2026). The sales were open-market or private transactions, with weighted average prices ranging from $130.0000 to $132.6514. These …

Insulet hires Pfizer alum Joan Campion to lead external comms

Insulet, a medical device company, has appointed Joan Campion, formerly of Pfizer, as its new VP of external communications for corporate affairs. This new role is part of a broader effort by Insulet to enhance its communications function under Chief Corporate Affairs Officer Cristal …

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Amgen Stock And The Price Of A Promise

Amgen recently raised its full-year revenue guidance, typically a positive signal, but its stock has not seen a significant celebratory pop. While the company's current performance is strong with multiple products showing double-digit growth, the market appears to have already factored this in. Investors …

Organon & Co. (OGN) CMO exercises 11,519 RSUs and withholds 4,134 shares for costs

Organon & Co.'s Chief Medical Officer, Juan Camilo Arjona Ferreira, exercised 11,519 restricted stock units (RSUs) on August 11, 2026, converting them into common shares. Concurrently, 4,134 common shares were withheld at $13.62 per share to cover exercise costs or tax liabilities. This transaction …

Listening to the Hemophilia Community: Pfizer Survey Reveals Unspoken Compromises

A Pfizer survey conducted with The Harris Poll found that many hemophilia patients and caregivers, while reporting satisfaction with current treatments, still experience significant burdens and make unspoken compromises in their daily lives. The survey, involving over 1,000 participants across four countries, highlighted challenges …

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, …

Gilead Sciences (GILD) Starts AI Biomarker Research Partnership For Oncology

Gilead Sciences has partnered with Nucleai for an AI-powered biomarker research collaboration aimed at improving precision oncology and supporting Gilead's antibody drug conjugate clinical programs. This initiative seeks to standardize biomarker analyses in clinical trials to develop more tailored cancer treatments. The collaboration comes …

Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

The article compares Johnson & Johnson (J&J) and AbbVie as investment options, focusing on their dividend characteristics and business strategies. J&J offers a safer, more diversified dividend with a 64-year streak and an AAA-rated balance sheet, while AbbVie provides a higher yield but carries …

Tigo Energy downgraded at Roth after weak revenue guidance

[Aerial view of large electrical power plant with many rows of solar photovoltaic panels for producing clean ecological electric energy in morning. Renewable electricity with zero emission concept.] Bilanol/iStock via Getty Images Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO]) down 5.2% in Wednesday's trading as Roth Capital …

Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses …

[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach …

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 …

Eli Lilly Stock Falls While Retatrutide Lawsuits Expand

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase …

Two Years Of Growth Barely Change What You Pay For Intuitive Surgical

Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high …

Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development …

Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales

Eli Lilly has filed six lawsuits against U.S. companies for allegedly selling unauthorized versions of its experimental obesity drug, retatrutide. The lawsuits target compounding pharmacies, medical spas, and online sellers, as retatrutide is still in Phase 3 clinical trials and not yet approved by …

Lilly Targets Black-Market Retatrutide Sellers

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY …

Why Bristol Myers Squibb (BMY) Is Back In The Spotlight

Eli Lilly sues six companies for selling illegal versions of groundbreaking weight-loss drug

Eli Lilly has filed lawsuits against six companies for illegally selling unapproved versions of its experimental weight-loss drug, retatrutide, which is still in Phase 3 trials. The pharmaceutical giant asserts that these black-market products are unverified and potentially life-threatening, and has called on social …